Stay updated with breaking news from Rating Scale. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Investegate announcements from Clinigen, Clinigen notes results from the MIROCALS trial investigating low dose Proleukin® (aldesleukin) in patients with amyotrophic lateral sclerosis
8 December 2022 Clinigen notes results from the MIROCALS trial investigating low dose Proleukin (aldesleukin) in patients with amyotrophic lateral sclerosis Clinigen Limited
/PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today...
/PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, today announced the...
Tofersen alone does not significantly change function in patients with faster progressing SOD1 amyotrophic lateral sclerosis.